Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,550 | 0,610 | 31.07. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
26.06. | JW THERAP-B (02126): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2025 | - | HKEx | ||
03.06. | JW THERAP-B (02126): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON JUNE 3, 2025 | 2 | HKEx | ||
28.05. | JW THERAP-B (02126): VOLUNTARY ANNOUNCEMENT - RESEARCH AND DEVELOPMENT UPDATE NMPA ACCEPTANCE OF THE SUPPLEMENTAL BIOLOGICAL LICENSE APPLICATION FOR CARTEYVA ... | - | HKEx | ||
15.05. | JW THERAP-B (02126): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON JUNE 3, 2025 | - | HKEx | ||
15.05. | JW THERAP-B (02126): NOTICE OF EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
15.05. | JW THERAP-B (02126): CONNECTED TRANSACTION IN RELATION TO LICENSE AGREEMENT | - | HKEx | ||
JW THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
14.05. | JW THERAP-B (02126): CLOSURE OF REGISTER OF MEMBERS | - | HKEx | ||
08.05. | JW THERAP-B (02126): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON JUNE 26, 2025 | - | HKEx | ||
08.05. | JW THERAP-B (02126): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
08.05. | JW THERAP-B (02126): PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES, TRANSFER SHARES OUT OF TREASURY AND REPURCHASE SHARES AND RE-ELECTION OF DIRECTORS ... | 3 | HKEx | ||
28.04. | JW THERAP-B (02126): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
28.04. | JW THERAP-B (02126): 2024 ANNUAL REPORT | 1 | HKEx | ||
22.04. | JW THERAP-B (02126): CONNECTED TRANSACTION IN RELATION TO THE LICENSE AGREEMENT AND FURTHER INFORMATION RELATING TO THE MATERIAL TRANSFER AGREEMENT | 2 | HKEx | ||
11.04. | JW THERAP-B (02126): GRANT OF SHARE OPTIONS | 3 | HKEx | ||
02.04. | JW THERAP-B (02126): NEXT DAY DISCLOSURE RETURN | 5 | HKEx | ||
27.03. | JW THERAP-B (02126): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 | - | HKEx | ||
19.03. | JW THERAP-B (02126): CONNECTED TRANSACTION IN RELATION TO MATERIAL TRANSFER AGREEMENT | - | HKEx | ||
17.03. | JW THERAP-B (02126): NOTICE OF BOARD MEETING | - | HKEx | ||
14.03. | JW THERAP-B (02126): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 5 | HKEx | ||
14.03. | JW THERAP-B (02126): CHANGE OF CHAIRMAN | 1 | HKEx |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 43,800 | -0,86 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für Qiagen von 47 auf 52 Euro angehoben und die Einstufung auf "Kaufen" belassen. Qiagen sei zurück auf dem Wachstumspfad, die operative... ► Artikel lesen | |
EVOTEC | 7,046 | -4,50 % | Nach dem Prognose-Schock: Zoll-Rallye: Evotec-Aktien legen kräftig zu! | © Foto: Christian Charisius/dpa - dpa-BildfunkDie Aktie des Hamburger Wirkstoffforschers klettert am Montag auf den höchsten Stand seit Mitte Juni. Auch andere Pharmawerte profitieren von der Zolleinigung... ► Artikel lesen | |
BIONTECH | 94,25 | +0,11 % | BioNTech SE: Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an LP.8.1 angepassten COVID-19-Impfstoff in der Europäischen Union | Daten zeigten, dass der an LP.8.1 angepasste COVID-19-Impfstoff verglichen mit den COVID-19-Impfstoffformulierungen 2024-2025 eine verbesserte Immunantwort gegen derzeit vorherrschende und neu auftretende... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,945 | 0,00 % | Recursion Pharmaceuticals: Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th | ||
AVIDITY BIOSCIENCES | 36,650 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory ... | -- Topline data readout from HARBOR study anticipated in Q2 2026 ---- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated... ► Artikel lesen | |
PSYENCE BIOMEDICAL | 5,140 | 0,00 % | Pre-market Movers: VerifyMe, Psyence Biomedical, Pineapple Financial, Align Technology, Confluent | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green VerifyMe, Inc. (VRME) is up over 79% at $1.23.
Psyence... ► Artikel lesen | |
ADMA BIOLOGICS | 18,700 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025 | ||
COGENT BIOSCIENCES | 11,410 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced ... | -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 26,350 | 0,00 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
MODERNA | 25,800 | -0,42 % | Moderna erhält EU-Zulassung für aktualisierten COVID-19-Impfstoff | Moderna hat von der Europäischen Kommission die Zulassung für die aktualisierte Version seines COVID-19-Impfstoffs Spikevax erhalten. Die neue Formulierung richtet sich gegen die SARS-CoV-2-Variante... ► Artikel lesen | |
DYNE THERAPEUTICS | 9,850 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights | - Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne's first planned commercial launch in early 2027 - - Registrational Expansion Cohort of DELIVER... ► Artikel lesen | |
BEAM THERAPEUTICS | 19,720 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
BB BIOTECH | 35,600 | +2,89 % | BB Biotech schreibt im Q2 erneut Verlust | Schaffhausen - BB Biotech ist auch im zweiten Quartal 2025 in der Verlustzone geblieben. Als Hauptgrund nennt die Beteiligungsgesellschaft Wechselkurseffekte. Zwischen April und Juni schrieb BB Biotech... ► Artikel lesen | |
PRAXIS PRECISION MEDICINES | 54,18 | -4,26 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies | The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The... ► Artikel lesen | |
JANUX THERAPEUTICS | 24,030 | -0,83 % | Raymond James startet Coverage für Janux Therapeutics mit "Outperform"-Rating |